Source comparison
Is Melanotan-1 Safe Side Effects: Dermatologic Comparison
Melanogenesis Mechanism Systemic MC1R agonism independent of UV exposure Controlled-release MC1R agonism over 60 days UV-induced DNA damage triggers melanin production Melanotan-1 bypasses the UV-damage pathway entirely. Tanning occurs without the inflammatory
This comparison does not assign a generated winner or score.
- Melanogenesis Mechanism
- Systemic MC1R agonism independent of UV exposure
- Controlled-release MC1R agonism over 60 days
- UV-induced DNA damage triggers melanin production
- Melanotan-1 bypasses the UV-damage pathway entirely. Tanning occurs without the inflammatory cascade that normally precedes pigmentation
- Nausea Incidence
- 40–70% during loading phase (dose-dependent)
- 34% in clinical trials (implant formulation)
- Rare (heat-related only)
- Injectable formulations produce higher peak plasma concentrations than implants, which correlates with increased GI adverse events
- Cardiovascular Effects
- Transient BP elevation 8–12 mmHg in 15–25% of subjects
- Minimal (sustained-release limits peak concentration)
- None melanogenesis-related
- Acute subcutaneous dosing produces sympathetic activation that implant formulations largely avoid through pharmacokinetic design
- Pigmentation Duration
- 4–8 weeks post-cessation (melanin turnover-dependent)
- 2–3 months (prolonged receptor occupancy)
- 2–4 weeks (epidermal turnover)
- Melanocortin-induced melanogenesis persists longer than UV-induced pigmentation because receptor-mediated synthesis continues beyond the initiating stimulus
- Regulatory Status
- Research use only (not FDA-approved for cosmetic tanning)
- FDA-approved for erythropoietic protoporphyria only
- Unregulated
- The same peptide carries different legal classifications depending on formulation and intended use. Researchers must distinguish between pharmaceutical-grade afamelanotide and research-grade peptide suppliers